Compare ADMA Biologics Inc (ADMA) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ProShares Ultra QQQ ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while ProShares Ultra QQQ ETF trades at $89.24. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QLD | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $100.53 |
52-Week Low | $7.60 | $57.16 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
QLD, the ProShares Ultra QQQ ETF, trades at $93.12, up 2.8% today, reflecting strong bullish momentum with a technical buy signal from moving averages. As a 2x leveraged ETF tracking the Nasdaq-100, it amplifies returns but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though it experienced significant drawdowns historically.
The outlook for QLD is tied to tech sector strength, with AI optimism and easing geopolitical tensions supporting growth. However, leveraged ETFs like QLD are high-risk tactical instruments unsuitable for long-term holdings due to daily rebalancing effects. Investors should weigh potential amplified gains against the risk of sharp declines in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
